CAMBRIDGE, April 5, 2016 – Eagle Genomics announces the results of a novel insight on the International Cancer Genome Consortium (https://icgc.org/) data, with over 17,000 patient donors, resulting in a ranking of the most valuable constituent projects according to their scientific value.
The analysis was performed using eaglediscover, a smart data platform which Eagle is releasing today. The eaglediscover platform objectively measures the value of data assets as defined by their usefulness and relevance. The approach uses robust quantitative and probabilistic techniques and methods from conversational theory Smart Data Science. The unique question-driven approach of eaglediscover allows scientists to explore scientific value across diverse data sets as never previously possible.
Projects studying large numbers of patients with common cancers generally scored highly with “The Cancer Genome Atlas (TCGA) Breast Cancer” taking top spot. But study size was not the only factor, with the smaller “Spanish Chronic Lymphocytic Leukemia” project coming in the top five. For patient selection, picking across multiple projects yielded significantly more valuable cohorts than limiting to a single project, with an even more pronounced advantage when restricting to specific cancer types and using Eagle Genomics proprietary valuation models calibrated for specific scientific questions.
Mathew Woodwark, Director of R&D Bioinformatics, MedImmune, has been seeking an effective "smart data" platform that enables MedImmune and AstraZeneca scientists to explore and value biological and clinical data sets. "We are actively working with Eagle Genomics on the use of eaglediscover with eaglecore to enable us to build a world-class R&D process for data prioritization and reuse. Eagle is leading the way in maximizing the value of data, one of the biggest data challenges facing pharma and biotech R&D today."
Abel Ureta-Vidal, Eagle Genomics CEO, comments “A major challenge today is that too much time is spent on data wrangling and not enough on scientific interpretation. With eaglediscover, we are breaking the loop of ‘data analysis paralysis’.”
Access to the eaglediscover ICGC analysis is available through the Eagle Genomics Early Adopter Program.
About Eagle Genomics
Eagle Genomics is a software company helping life sciences companies conducting genomics research to bring new candidate medicines, therapies and products to patients and customers more quickly. Its software solutions exploit smart data science and deep statistics to radically reduce time to complete and cost of research, thus enabling customers to achieve drastic productivity improvements and enable true data driven discovery.